A61K 2039/6025
Nucleotides
Official title: {Nucleotides}
A61K2039/6025 (Nucleotides) appears on 39 US grants and 83 published applications in this corpus.
Search patents in A61K- Granted patents
- 39
- Published applications
- 83
- Assignees
- 57
- Inventors
- 191
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 2 | 6 |
| 2004 | 0 | 4 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 2 | 6 |
| 2008 | 2 | 4 |
| 2009 | 3 | 3 |
| 2010 | 3 | 2 |
| 2011 | 0 | 4 |
| 2012 | 3 | 2 |
| 2013 | 1 | 1 |
| 2014 | 1 | 1 |
| 2015 | 2 | 6 |
| 2016 | 0 | 3 |
| 2017 | 2 | 5 |
| 2018 | 1 | 3 |
| 2019 | 4 | 5 |
| 2020 | 2 | 2 |
| 2021 | 5 | 4 |
| 2022 | 2 | 2 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 1 | 3 |
| 2026 | 2 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nucleic acid nanostructure platform for programming immune stimulation2 Jun 2026US 12,642,850 B2Massachusetts Institute of Technology
- Composition for delivery of a bioactive agent and method of manufacture and use thereof5 May 2026US 12,616,754 B2National Cheng Kung University
- Hybrid immolative cell-penetrating complexes for nucleic acid delivery4 Feb 2025US 12,215,341 B2The Board of Trustees of the Leland Stanford Junior University
- Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom23 Aug 2022US 11,419,932 B2Massachusetts Institute of Technology
- Vaccine RNA-peptide against SARS-CoV-2 with endogenous exosomes as carrier15 Feb 2022US 11,246,922 B1Elidan America, LLC.
- Peptide linkers for modulating antigen immune response in cancer vaccines27 Aug 2026US 2026/0248899 A1Northwestern University
- Nucleic acid adjuvant16 Jul 2026US 2026/0201392 A1Aomori Yamada Gakuen Educational Corporation
- Nanoparticle-oligot conjugates based messenger rna delivery system2 Jul 2026US 2026/0183382 A1Nes Biotechnology Co., Ltd.
- Therapeutic compound and method of preparing a therapeutic vaccine for the treatment of allergic and autoimmune diseaes using immunization with engineered bacterial dna or cpg motifs derivide from commensal bacteria such as bifidobacterium longun subsp. infantis.23 Apr 2026US 2026/0108599 A1
- Peptide and nucleic acid methods to modulate delivery of nucleic acid structures, polypeptides, and their cargoes19 Mar 2026US 2026/0077027 A1Ohio State Innovation Foundation
Most cited
By later US patents
- Immunostimulatory polynucleotide/immunomodulatory molecule conjugates162US 6,610,661 B1The Regents of the University of California · 2003
- Immunostimulatory polynucleotide/immunomodulatory molecule conjugates97US 7,208,478 B2The Regents of the University of California · 2007
- Methods for increasing a cytotoxic T lymphocyte response in vivo72US 6,534,062 B2The Regents of the University of California · 2003
- Chemically programmable immunity58US 7,850,975 B2Altermune Technologies, LLC · 2010
- Chemically programmable immunity50US 8,591,910 B2Altermune Technologies, LLC · 2013